Literature DB >> 20882091

[Progress in understanding the pathogenesis of IgA nephropathy: new perspectives for the near future?].

A Segarra1.   

Abstract

Progress in understanding the pathogenesis of IgA nephropathy has shown that probably there is no a single IgA nephropathy with the same pathogenic mechanism, clinical course and response to therapy. The evidence currently available suggests the existence of at least two possible mechanisms of IgA deposition in the renal mesangium. In a small percentage of patients, mesangial deposition of IgA1 colocalizes with secretory component, indicating that the deposited IgA1 in glomeruli originates completely or partly in the mucose-associated lymphoid tissue. This deposition pattern has been associated with activation of complement by the lectin pathway and has been associated with a worse prognosis, although this last statement needs to be confirmed in long-term studies. The mechanisms responsible for secretory IgA deposition are not known. In the majority of patients with IgA nephropathy secretory component is not detectable in the mesangium. In these cases, the presence of elevated circulating levels of galactose-deficient IgA, produced by bone marrow plasma cells would be a predisposing factor but not sufficient to induce nephropathy. To produce kidney disease, galactose-deficient IgA1 must be deposited in the renal mesangium, and once there, either by interaction with specific receptors (CD71?), by direct activation of complement or by being the target of an IgG autoimmune response anti-IgA, induce activation, proliferation and increased mesangial matrix synthesis and eventually cell injury. In parallel, galactose-deficient IgA, through interaction with the RR Fc alpha/gamma, may activate circulating lymphocytes and monocytes and enhance their response to chemoattractants produced by the mesangial cell, causing, thus, the inflammatory infiltrate to initiate and maintain the interstitial injury. In the next few years, advances recently added to the knowledge of the pathogenesis of nephropathy IgA1 could provide new variables that allow walking in the direction of having a classification of patients based not only in clinical and morphological criteria but also having a greater pathogenic basis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20882091     DOI: 10.3265/Nefrologia.pre2010.Jul.10526

Source DB:  PubMed          Journal:  Nefrologia        ISSN: 0211-6995            Impact factor:   2.033


  4 in total

1.  Intermedin ameliorates IgA nephropathy by inhibition of oxidative stress and inflammation.

Authors:  Yanhong Wang; Jihua Tian; Haixiu Guo; Yang Mi; Ruijing Zhang; Rongshan Li
Journal:  Clin Exp Med       Date:  2015-04-28       Impact factor: 3.984

2.  Icariin ameliorates IgA nephropathy by inhibition of nuclear factor kappa b/Nlrp3 pathway.

Authors:  Lei Zhang; Xing-Zhi Wang; Yu-Shu Li; Lei Zhang; Li-Rong Hao
Journal:  FEBS Open Bio       Date:  2016-12-20       Impact factor: 2.693

3.  Urinary proteomic shotgun approach for identification of potential acute rejection biomarkers in renal transplant recipients.

Authors:  Håvard Loftheim; Karsten Midtvedt; Anders Hartmann; Anna V Reisæter; Pål Falck; Hallvard Holdaas; Trond Jenssen; Leon Reubsaet; Anders Asberg
Journal:  Transplant Res       Date:  2012-08-31

4.  The protective effect and mechanism of rapamycin in the rat model of IgA nephropathy.

Authors:  Ning Guo; Shengli Liu; Laurine M Bow; Xianquan Cui; Luwei Zhang; Shihao Xu; Sai Lu; Jun Tian
Journal:  Ren Fail       Date:  2019-11       Impact factor: 2.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.